J‐ALEX study conducted in Japanese patients13 and global ALEX study7 directly compared alectinib and crizotinib in patients with advanced ALK‐positive NSCLC, whereby alectinib achieved significantly better PFS. Here, ALK is linked to non-small cell lung carcinoma.